Atopic dermatitis (AD) is far more than just dry, itchy skin. This chronic, relapsing inflammatory disorder disrupts lives globally, with pediatric prevalence reaching 15–30% and adult rates ranging from 2.1% to 8.1% across regions. Beyond physical discomfort, AD contributes to sleep disturbances, anxiety, and even comorbidities like asthma and allergic rhinitis, making effective management a critical unmet need. Recent research has revolutionized our understanding of AD—shifting focus from symptom control to addressing root causes like skin barrier dysfunction and immune dysregulation. Let’s explore the latest evidence-based advancements in AD care, grounded in rigorous clinical studies and scientific discovery.

The Skin Barrier: The Forgotten Foundation of AD Management

For decades, AD treatment centered on suppressing inflammation, but emerging research highlights the skin barrier as a key player in both prevention and treatment. The skin’s barrier system—comprising physical, chemical, immune, and microbial components—acts as the body’s first line of defense against irritants and allergens. In AD patients, this barrier is compromised: ceramide levels (critical for lipid bilayer structure) are reduced by 60%, filaggrin (a structural protein) is often deficient, and transepidermal water loss (TEWL) is significantly elevated. This dysfunction creates a vicious cycle: a damaged barrier allows allergens to penetrate, triggering inflammation that further impairs barrier function.

Restoring the skin barrier has emerged as a cornerstone of AD care. A 2025 narrative review emphasizes that barrier repair is not just supportive care but a therapeutic necessity—reducing relapse rates and improving long-term outcomes. Moisturizers, long considered basic skincare, are now recognized as first-line treatments. Ceramide-based formulations, for example, have been shown to significantly reduce TEWL and improve skin hydration, with one multicenter study reporting a 61.2% reduction in SCORAD scores (a key AD severity metric) after just four weeks of use. Colloidal oatmeal and plant-derived ingredients like licochalcone A also show promise, with licochalcone A demonstrating comparable efficacy to low-potency corticosteroids while reducing relapse rates by 42.9% compared to steroid monotherapy.

Phototherapy: Harnessing Light for Localized Relief

For patients with localized or moderate AD, phototherapy offers a safe, drug-free alternative—especially when topical treatments fall short. Among the most promising light-based therapies is 308-nm excimer light, which targets lesions with precise, high-intensity ultraviolet radiation. A 2023 preliminary clinical study of Korean adults found that twice-weekly 308-nm excimer light treatment for four weeks significantly improved AD severity (p<0.001) and enhanced skin barrier function (p<0.01) compared to control groups. The therapy works by reducing inflammatory cellular infiltrate, lowering serum IgE levels, and restoring skin barrier integrity—effects validated in both animal models and human trials.

In a 2008 clinical trial involving 18 adults and children with localized AD, 66.7% achieved complete remission after 6–12 weekly sessions of 308-nm monochromatic excimer light, with 44% maintaining results at 16-week follow-up. Notably, the therapy is well-tolerated across age groups, making it a versatile option for patients where systemic treatments may be contraindicated. Brazilian dermatology experts further endorse phototherapy—including 308-nm excimer light—as a valid alternative for moderate-to-severe AD refractory to topical care.

Systemic Therapies: Targeting Inflammation at Its Source

For moderate-to-severe AD, systemic therapies have evolved beyond broad immunosuppressants to precision-targeted treatments. Conventional options like ciclosporin and methotrexate remain useful—with ciclosporin showing comparable efficacy to newer biologics in short-term use—but newer agents offer improved safety and specificity.

Biologics: Blocking Pathogenic Cytokines

Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 (key drivers of AD inflammation), has transformed severe AD care. Multiple studies confirm its ability to restore skin barrier function: a 2022 trial found that 16 weeks of dupilumab normalized TEWL in lesional skin to healthy control levels, while also improving ceramide profiles and filaggrin processing. Notably, these benefits extend to children as young as 6 months, with phase 3 trials showing significant reductions in skin infections and symptom severity across pediatric age groups.

JAK Inhibitors: A New Class of Oral Therapies

Janus kinase (JAK) inhibitors—including upadacitinib and abrocitinib—offer oral alternatives for patients who prefer not to use injectable biologics. Upadacitinib, a selective JAK1 inhibitor, demonstrated superior efficacy to dupilumab in head-to-head trials, with 71% of patients achieving EASI-75 (75% reduction in Eczema Area and Severity Index) at 16 weeks compared to 61.1% in the dupilumab group. Abrocitinib, another JAK1 inhibitor, shows rapid itch relief—often within 24 hours—and maintains efficacy even in patients who previously failed dupilumab treatment. Brazilian guidelines now recommend these agents for moderate-to-severe AD when conventional therapies are inadequate.

The Future of AD Care: Personalization and Prevention

The most exciting advancements in AD management lie in personalized medicine. Researchers are moving toward multi-omics-driven interventions—using lipidomics, metabolomics, and genetic testing to tailor treatments to individual patients. For example, patients with filaggrin mutations may benefit more from ceramide-rich moisturizers, while those with Th2-dominant inflammation may respond best to dupilumab or JAK inhibitors.

Early intervention is another promising frontier. A 2023 randomized controlled trial found that early emollient use in high-risk infants reduced AD incidence, highlighting the potential to prevent the disease before it develops. Additionally, microbial interventions—including probiotics and prebiotics—aim to restore the skin’s microbiome balance, which is disrupted in AD (with Staphylococcus aureus overgrowth up to 10-fold higher in lesions compared to healthy skin).

Key Takeaways for Patients and Providers

AD management has evolved from a one-size-fits-all approach to a personalized strategy that integrates barrier repair, targeted inflammation control, and patient preferences. For mild AD, prioritize ceramide-based moisturizers and gentle skincare to restore barrier function. For localized moderate disease, 308-nm excimer light offers safe, effective relief. For severe AD, biologics and JAK inhibitors provide durable symptom control with manageable safety profiles.

As research advances, the goal is clear: to shift AD care from reactive symptom management to proactive barrier maintenance and personalized treatment. By combining evidence-based therapies with a focus on skin health fundamentals, patients can break the cycle of flares and reclaim quality of life.

References

1. Fonda-Pascual P, Collantes-Rodriguez C, Sanchez-Los Arcos L, et al. Effectiveness of 308-nm excimer lamp in the treatment of notalgia paresthetica. J Eur Acad Dermatol Venereol. 2021;35(2):e111-e113. https://doi.org/10.1111/jdv.16836
2. Chen X. Skin Barrier Repair and Nursing Care in Patients with Atopic Dermatitis: A Narrative Review. Int J Gen Med. 2025;18:6803–6819. https://doi.org/10.2147/IJGM.S542311
3. Nisticò SP, Saraceno R, Capriotti E, et al. Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children. Photomed Laser Surg. 2008;26(1):14-8. https://doi.org/10.1089/pho.2007.2116
4. Park BG, Seul TW, Shin JJ, et al. Preliminary Clinical Study of the Effects and Safety of 308-nm Excimer Light Treatment in Patients with Atopic Dermatitis. Ann Dermatol. 2023;35(6):417-423. https://doi.org/10.5021/ad.22.223
5. Orfali RL, Lorenzini D, Bressan A, et al. Consensus on the therapeutic management of atopic dermatitis ‒ Brazilian Society of Dermatology: an update on phototherapy and systemic therapy using e-Delphi technique. An Bras Dermatol. 2023;98(6):814–836. https://doi.org/10.1016/j.abd.2023.04.003
6. Oh CT, Kwon TR, Seok J, et al. Effect of a 308-nm excimer laser on atopic dermatitis-like skin lesions in NC/Nga mice. Lasers Surg Med. 2016;48(6):629-37. https://doi.org/10.1002/lsm.22524